DiaMedica Starts Relaunched Phase 2/3 Trial for Acute Stroke Treatment
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for neurological disorders and cardio-renal disease, has disclosed the dosing of the first patient in its relaunched Phase 2/3 ReMEDy2 Trial of DM199 for acute ischemic stroke…
Saghmos Therapeutics Teams Up with Duke for Phase 3 Study
Saghmos Therapeutics, Inc. (Saghmos), a privately owned biopharmaceutical firm, has disclosed its collaboration with the Duke Clinical Research Institute (DCRI) to enhance and strategize the implementation of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516. Saghmos Therapeutics, Inc.…
Butterfly Network, CHAI, and Global Ultrasound Institute join forces for maternal and fetal health in South Africa.
Butterfly Network, Inc. (“Butterfly”), a pioneering digital health company focused on revolutionizing healthcare with portable, semiconductor-based ultrasound technology and user-friendly software, has announced a collaborative effort involving three key players: the Clinton Health Access Initiative (CHAI), a globally recognized health…
Identiv Welcomes Kirsten Newquist as IoT Solutions President
Identiv, Inc. (NASDAQ: INVE), a worldwide leader in digital security and identification within the Internet of Things (IoT) realm, has welcomed Kirsten Newquist to its team. With nearly three decades of experience in building thriving businesses, Ms. Newquist joins as…
Fullscript Hosts Cardiometabolic Summit with Industry Leaders
Fullscript, a prominent figure in healthcare platforms designed for comprehensive care, has revealed its plans to organize a virtual Cardiometabolic Summit on April 17-18th, 2024. This summit aims to bring together a diverse audience comprising both conventional and functional clinicians.…
Alula Technologies and ROOK Team Up for Wearable Health Data Innovation in Insurance
Exciting Partnership: Alula Technologies Joins Forces with ROOK, a Pioneer in Wearable Health Data Platform Alula, renowned for its AI-driven technology solutions enhancing customer experiences and risk understanding, partners with ROOK, a trailblazer in wearable health data platforms. Alula’s expertise…
ArthritisPower® Registry Expands to PatientSpot™
The Global Healthy Living Foundation (GHLF) is excited to announce a major milestone in its commitment to aiding individuals with chronic diseases. ArthritisPower, a respected disease tracking platform and research registry since 2014, has evolved into PatientSpot — a comprehensive…
LabVantage Marks Record Software Deployments in FY 2024
LabVantage Solutions, Inc., a leading provider of laboratory IT solutions, has announced the completion of over 100 software deployments in fiscal year 2024 across various industries, including pharmaceuticals, biotechnology, healthcare, oil and gas, and food and beverage. The global LIMS…
Saga University, BostonGene Research Biomarkers for EGFR+ Lung Cancer Treatment Efficacy
On April 16, 2024, Saga University Hospital and BostonGene (based in Waltham, Massachusetts, U.S.) forged a collaboration aimed at advancing biomarker research to predict the efficacy of immune checkpoint inhibitors (ICI) in patients with EGFR-positive lung cancer. Saga University Hospital,…
Novo Integrated Sciences Q2 2024 Financial Report
Novo Integrated Sciences, Inc. (NASDAQ:NVOS), a pioneer in patient-centric health and wellness, announced its financial results for the second fiscal quarter ending February 29, 2024. Robert Mattacchione, Novo’s CEO and Board Chairman, highlighted efforts during the quarter to enhance operational…
Edgewise’s Sevasemten Shows Positive Two-Year Results in Becker Muscular Dystrophy Trial
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has unveiled encouraging two-year topline results from the ARCH trial. The ARCH study, conducted at a single center, is an open-label investigation focusing on assessing safety, tolerability,…
Fresenius Speeds Up Pharma Growth, Releases Tyenne® Biosimilar in U.S.
Fresenius Kabi, a division of Fresenius, has launched Tyenne® (tocilizumab-aazg) in the U.S., a biosimilar of Actemra® (tocilizumab), approved by the FDA on March 5, 2024. Tyenne® is available in both intravenous and subcutaneous formulations, marking a significant advancement in…